-Ketobenzothiazole Serine Protease Inhibitors of Aberrant HGF/c-MET and MSP/RON Kinase Pathway Signaling in Cancer

被引:28
作者
Han, Zhenfu [1 ]
Harris, Peter K. W. [1 ]
Karmakar, Partha [1 ]
Kim, Tommy [1 ]
Owusu, Ben Y. [2 ]
Wildman, Scott A. [1 ,3 ]
Klampfer, Lidija [2 ]
Janetka, James W. [1 ]
机构
[1] Washington Univ, Sch Med, Alvin J Siteman Canc Ctr, Dept Biochem & Mol Biophys, 660 S Euclid Ave, St Louis, MO 63110 USA
[2] So Res Inst, Dept Oncol, 2000 9th Ave, Birmingham, AL 35205 USA
[3] Univ Wisconsin, Carbone Canc Ctr, Sch Med & Publ Hlth, Madison, WI 53792 USA
关键词
cancer; cell signaling; metastasis; serine protease inhibitors; solid-phase peptide synthesis; structure-based drug design; HEPATOCYTE GROWTH-FACTOR; MACROPHAGE-STIMULATING PROTEIN; BREAST-CANCER; SELECTIVE INHIBITORS; FACTOR ACTIVATOR; CELL-LINES; C-MET; PROGNOSTIC-SIGNIFICANCE; MATRIPTASE INHIBITORS; ONCOGENE ADDICTION;
D O I
10.1002/cmdc.201500600
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Upregulation of the HGF and MSP growth-factor processing serine endopeptidases HGFA, matriptase and hepsin is correlated with increased metastasis in multiple tumor types driven by c-MET or RON kinase signaling. We rationally designed P1' -ketobenzothiazole mechanism-based inhibitors of these proteases. Structure-activity studies are presented, which resulted in the identification of potent inhibitors with differential selectivity. The tetrapeptide inhibitors span the P1-P1' substrate cleavage site via a P1' amide linker off the benzothiazole, occupying the S3' pocket. Optimized inhibitors display sub-nanomolar enzyme inhibition against one, two, or all three of HGFA, matriptase, and hepsin. Several compounds also have good selectivity against the related trypsin-like proteases, thrombin and FactorXa. Finally, we show that inhibitors block the fibroblast (HGF)-mediated migration of invasive DU145 prostate cancer cells. In addition to prostate cancer, breast, colon, lung, pancreas, gliomas, and multiple myeloma tumors all depend on HGF and MSP for tumor survival and progression. Therefore, these unique inhibitors have potential as new therapeutics for a diverse set of tumor types.
引用
收藏
页码:585 / 599
页数:15
相关论文
共 61 条
[1]   Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors and Therapeutic Approaches: An Update [J].
Ahsan, Aarif .
LUNG CANCER AND PERSONALIZED MEDICINE: CURRENT KNOWLEDGE AND THERAPIES, 2016, 893 :137-153
[2]   Ron Kinase Transphosphorylation Sustains MET Oncogene Addiction [J].
Benvenuti, Silvia ;
Lazzari, Luca ;
Arnesano, Addolorata ;
Chiavi, Giulia Li ;
Gentile, Alessandra ;
Comoglio, Paolo M. .
CANCER RESEARCH, 2011, 71 (05) :1945-1955
[3]   Strong expression association between matriptase and its substrate prostasin in breast cancer [J].
Bergum, Christopher ;
Zoratti, Gina ;
Boerner, Julie ;
List, Karin .
JOURNAL OF CELLULAR PHYSIOLOGY, 2012, 227 (04) :1604-1609
[4]   Coordinate expression and functional profiling identify an extracellular proteolytic signaling pathway [J].
Bhatt, Ami S. ;
Welm, Alana ;
Farady, Christopher J. ;
Vasquez, Maximiliano ;
Wilson, Keith ;
Craik, Charles S. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (14) :5771-5776
[5]   Roles of c-Met and RON Kinases in tumor progression and their potential as therapeutic targets [J].
Chang, Katherine ;
Karnad, Anand ;
Zhao, Shujie ;
Freeman, James W. .
ONCOTARGET, 2015, 6 (06) :3507-3518
[6]  
Chen QY, 1997, HEPATOLOGY, V26, P59
[7]   Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder [J].
Cheng, HL ;
Liu, HS ;
Lin, YJ ;
Chen, HHW ;
Hsu, PY ;
Chang, TY ;
Ho, CL ;
Tzai, TS ;
Chow, NH .
BRITISH JOURNAL OF CANCER, 2005, 92 (10) :1906-1914
[8]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[9]   Design and Synthesis of Potent, Selective Inhibitors of Matriptase [J].
Colombo, Eloic ;
Desilets, Antoine ;
Duchene, Dominic ;
Chagnon, Felix ;
Najmanovich, Rafael ;
Leduc, Richard ;
Marsault, Eric .
ACS MEDICINAL CHEMISTRY LETTERS, 2012, 3 (07) :530-534
[10]   In-depth study of tripeptide-based α-ketoheterocycles as inhibitors of thrombin.: Effective utilization of the S1′ subsite and its implications to structure-based drug design [J].
Costanzo, MJ ;
Almond, HR ;
Hecker, LR ;
Schott, MR ;
Yabut, SC ;
Zhang, HC ;
Andrade-Gordon, P ;
Corcoran, TW ;
Giardino, EC ;
Kauffman, JA ;
Lewis, JM ;
de Garavilla, L ;
Haertlein, BJ ;
Maryanoff, BE .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (06) :1984-2008